Drug Trial Radar · NCT04107168
Microbiome Immunotherapy Toxicity and Response Evaluation
Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,800
Planned (sponsor's estimate)
Start
Jul 8, 2020
Primary completion
Jul 8, 2024
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- CCTU- Cancer ThemeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Microbiotica Ltd
- First posted
- Sep 27, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
Conditions
- Melanoma
- Renal Cancer
- Lung Cancer
Interventions
NivolumabDrug
A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
PembrolizumabDrug
A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
IpilimumabDrug
A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
DurvalumabDrug
A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
TremelimumabDrug
A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
AtezolizumabDrug
A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
BevacizumabDrug
A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Can the microbiome signature predict progression-free survival (PFS) of 1 year or greaterTime frame: Minimum 1 year PFS
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Royal United Hospitals Bath NHS Foundation Trust
Bath, United Kingdom · Recruiting
University Hospitals Dorest NHS Foundation Trust
Bournemouth, United Kingdom · Recruiting
University Hospitals Bristol NHS Foundation Trust
Bristol, United Kingdom · Recruiting
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom · Recruiting
Velindre University NHS Trust
Cardiff, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
Kings Lynn, United Kingdom · Recruiting
University Hospitals of Leicester NHS Foundation Trust
Leicester, United Kingdom · Recruiting
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich, United Kingdom · Recruiting
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom · Recruiting
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom · Recruiting
Somerset NHS Foundation Trust
Taunton, United Kingdom · Recruiting
Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.